Cargando…

Anti-Anaplastic Thyroid Cancer (ATC) Effects and Mechanisms of PLX3397 (Pexidartinib), a Multi-Targeted Tyrosine Kinase Inhibitor (TKI)

SIMPLE SUMMARY: Anaplastic thyroid cancer (ATC) is the highest lethal type of thyroid cancer. Regrettably, ATC patients respond poorly to multiple treatment strategies. Therefore, there is imperative to strengthen the therapeutic approach to this vicious form of cancer. In the present study, we foun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Jingtao, Wang, Yun, Zhao, Lingkun, Wang, Chunli, Zhang, Ze
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817966/ https://www.ncbi.nlm.nih.gov/pubmed/36612171 http://dx.doi.org/10.3390/cancers15010172

Ejemplares similares

A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
por: Piawah, Sorbarikor, et al.
Publicado: (2019)

Pexidartinib (PLX3397) through restoring hippocampal synaptic plasticity ameliorates social isolation-induced mood disorders
por: Wang, Laifa, et al.
Publicado: (2022)

Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature
por: Giustini, Nicholas, et al.
Publicado: (2018)

A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor
por: Rosenbaum, Evan, et al.
Publicado: (2019)

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors
por: Wesolowski, Robert, et al.
Publicado: (2019)

Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis
por: Thongchot, Suyanee, et al.
Publicado: (2022)

Results of combined treatment of anaplastic thyroid carcinoma (ATC)
por: Derbel, Olfa, et al.
Publicado: (2011)

Distinguishing the effects of systemic CSF1R inhibition by PLX3397 on microglia and peripheral immune cells
por: Okojie, Akhabue K., et al.
Publicado: (2023)

Depletion of microglia with PLX3397 attenuates MK-801-induced hyperactivity associated with regulating inflammation-related genes in the brain
por: Ni, Rong-Jun, et al.
Publicado: (2023)

Suppression of Microgliosis With the Colony-Stimulating Factor 1 Receptor Inhibitor PLX3397 Does Not Attenuate Memory Defects During Epileptogenesis in the Rat
por: Wyatt-Johnson, Season K., et al.
Publicado: (2021)

MiRNA Deregulation Distinguishes Anaplastic Thyroid Carcinoma (ATC) and Supports Upregulation of Oncogene Expression
por: Misiak, Danny, et al.
Publicado: (2021)

Inhibition of Colony-Stimulating Factor 1 Receptor by PLX3397 Prevents Amyloid Beta Pathology and Rescues Dopaminergic Signaling in Aging 5xFAD Mice
por: Son, Yeonghoon, et al.
Publicado: (2020)

Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality
por: Zahir, Hamim, et al.
Publicado: (2022)

Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC–MS-Based Metabolomic Approaches
por: Qin, Xuan, et al.
Publicado: (2023)

Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2019)

3397 Genetic variants in gestational diabetes mellitus
por: Kothiyal, Prachi, et al.
Publicado: (2019)

MON-521 An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib (LEN) for the Treatment of Anaplastic Thyroid Cancer (ATC)
por: Wirth, Lori J, et al.
Publicado: (2020)

Correction to: Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2020)

ATC -> ICD – evaluating the reliability of prognoses for ICD-10 diagnoses derived from the ATC-Code of prescriptions
por: Weisser, Andrea, et al.
Publicado: (2008)

Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease
por: Sosna, Justyna, et al.
Publicado: (2018)

Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
por: Su, Xi, et al.
Publicado: (2021)

Dynamics of ACTH-Mediated Regulation of Gene Transcription in ATC1 and ATC7 Adrenal Zona Fasciculata Cell Lines
por: Hazell, Georgina, et al.
Publicado: (2019)

The assessment of side effects of tyrosine kinase inhibitors (TKI) applied in patients with advanced thyroid cancer (TC) - one centre experience
por: Krajewska, Jolanta, et al.
Publicado: (2013)

Novel Zinc(II) Complexes [Zn(atc-Et)(2)] and [Zn(atc-Ph)(2)]: In Vitro and in Vivo Antiproliferative Studies
por: Lopes, Erica de O., et al.
Publicado: (2016)

PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET
por: van Dongen, Guus A. M. S., et al.
Publicado: (2012)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
por: Stanchina, Michele, et al.
Publicado: (2020)

Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors
por: Zhou, F., et al.
Publicado: (2023)

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors
por: Gelderblom, Hans, et al.
Publicado: (2020)

Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Wang, Li, et al.
Publicado: (2021)

Discovery of Small-Molecule Allosteric Inhibitors of PfATC as Antimalarials
por: Wang, Chao, et al.
Publicado: (2022)

Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2019)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
por: Wang, Yuan, et al.
Publicado: (2022)

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2022)

Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces
por: Huang, Hao
Publicado: (2018)

OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility
por: Cabanillas, Maria, et al.
Publicado: (2019)

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs
por: Breccia, Massimo, et al.
Publicado: (2014)

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018)

Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity
por: Gu, Xiaoying, et al.
Publicado: (2021)

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects
por: Zahir, Hamim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t0qmgpi3ei5t1qgpdn474vj4nf